Single Blog

What Is Bempedoic Acid and Why Is It Different?

Bempedoic acid is a first-in-class, oral, non-statin lipid-lowering drug designed for adults with elevated LDL-cholesterol who either cannot tolerate statins or fail to reach guideline-recommended LDL targets despite maximally tolerated therapy. It belongs to a new generation of small-molecule agents that target cholesterol synthesis upstream of the classic statin pathway.

Unlike statins, which inhibit HMG‑CoA reductase in both liver and skeletal muscle, bempedoic acid selectively inhibits ATP‑citrate lyase (ACL), an enzyme one step earlier in the cholesterol biosynthesis cascade. Crucially, it is a prodrug that is activated primarily in the liver and not in muscle, which may explain its lower risk of muscle-related adverse effects compared with statins (doi:10.1056/NEJMoa1803917).

How Does Bempedoic Acid Work in the Body?

After oral administration, bempedoic acid is taken up by hepatocytes and converted to its active CoA form by very‑long‑chain acyl‑CoA synthetase‑1 (ACSVL1). This activating enzyme is highly expressed in the liver but minimally expressed in skeletal muscle, giving bempedoic acid its “liver-selective” pharmacology.

Once activated, bempedoic acid inhibits ACL, reducing the hepatic pool of acetyl‑CoA available for cholesterol synthesis. In response, the liver upregulates LDL receptors on hepatocyte surfaces, enhancing clearance of LDL-cholesterol from the circulation. In phase 3 trials, this mechanism translated into:

• Approximately 17–28% additional LDL‑C reduction on top of background statin therapy
• Even greater LDL‑C reductions when combined with ezetimibe

These effects were observed consistently across patients with established atherosclerotic cardiovascular disease (ASCVD) and heterozygous familial hypercholesterolemia (doi:10.1056/NEJMoa1803917).

Key Clinical Evidence: From LDL Lowering to Outcomes

The pivotal CLEAR Outcomes trial moved bempedoic acid from “LDL-lowering add-on” to a therapy with proven cardiovascular benefit. In more than 13,000 statin-intolerant patients at high cardiovascular risk, bempedoic acid demonstrated:

• Significant LDL‑C reductions versus placebo at 6 months
• A 13% relative reduction in major adverse cardiovascular events (MACE)
• A safety profile broadly similar to placebo, with some predictable metabolic signals

These data confirm that LDL lowering with bempedoic acid translates into fewer cardiovascular events, aligning it with the “LDL hypothesis” established for statins and PCSK9 inhibitors (doi:10.1056/NEJMoa2215024).

Who Might Benefit Most from Bempedoic Acid?

1. Statin‑Intolerant Patients

For patients who experience muscle pain, weakness, or creatine kinase elevations on multiple statins, bempedoic acid offers an oral, non-statin alternative. Its liver-selective activation makes it particularly attractive when myalgia limits dose escalation or forces discontinuation of statins.

2. Patients with Very High Baseline LDL‑C

Individuals with familial hypercholesterolemia or established ASCVD often require combination therapy. Bempedoic acid can be layered on top of maximally tolerated statins and/or ezetimibe before escalating to injectable PCSK9 inhibitors, potentially improving LDL control while delaying higher-cost biologics.

3. Patients Preferring Oral Therapy Over Injectables

Some patients are reluctant to initiate injectable therapies such as PCSK9 monoclonal antibodies or siRNA agents. For them, once-daily bempedoic acid provides a convenient, oral option with outcome data to support its use.

Safety Profile and Practical Considerations

Bempedoic acid is generally well tolerated, but clinicians should be aware of several class-specific safety signals:

• Uric acid and gout: Mild increases in serum uric acid and a higher incidence of gout, particularly in patients with a prior history
• Renal and hepatic labs: Small, usually reversible increases in serum creatinine and liver enzymes in some patients
• Tendon disorders: Rare cases of tendon rupture, warranting caution in patients with prior tendon disease or concurrent fluoroquinolone or systemic steroid use

Routine monitoring of uric acid, liver enzymes, renal function, and musculoskeletal symptoms is advisable, especially in high-risk individuals (doi:10.1056/NEJMoa1803917).

Future Directions: Combination Therapy and Precision Lipid Management

Fixed-dose combinations of bempedoic acid with ezetimibe are already available in some regions, simplifying multi-drug regimens and potentially improving adherence. Ongoing research is exploring:

• Its role in primary prevention in moderate-risk patients without established ASCVD
• Cost-effectiveness compared with PCSK9 inhibitors and other advanced lipid-lowering therapies
• Integration into personalized lipid-lowering algorithms guided by genetics, polygenic risk scores, and AI-driven cardiovascular risk prediction (doi:10.1056/NEJMoa2215024)

As cardiovascular prevention moves toward precision medicine, bempedoic acid exemplifies how pathway-selective, liver-targeted small molecules can expand our toolkit beyond statins—offering new hope for patients who previously had limited options to control LDL-cholesterol and reduce cardiovascular risk.

References

Ballantyne CM et al. N Engl J Med. 2018;378:641‑651. doi:10.1056/NEJMoa1803917

Nissen SE et al. N Engl J Med. 2023;388:1353‑1364. doi:10.1056/NEJMoa2215024